CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 77 enrolled / 77 target
Drug / intervention
RMP-A03 - Dose 1 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05794204
NCT05794204Phase 2CompletedOn Track (2.1/mo)Completion was 29mo ago
CompareCT.gov

A Phase 1/2a Study Evaluating the Safety and Efficacy of RMP-A03 Ocular Suspension in Healthy Volunteers and Patients With Pterygium

Suzhou Raymon Pharmaceuticals Company, Ltd.·interventional·Posted Apr 3, 2023·Updated Jun 5, 2026

In Brief

A Phase 2 clinical trial evaluating RMP-A03 - Dose 1, RMP-A03 - Dose 2, and 1 other intervention for Pterygium. Completed, enrolled 77 participants across 6 sites.

Detailed Summary

The goal of this clinical trial is to test the safety and efficacy of an ocular medication on the treatment of pterygium.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPterygium
CountriesUnited States
CollaboratorsWuXi Clinical

Timeline

Phase 2CompletedFinished
202420252026
First PostedApr 3, 2023
Enrollment StartJun 9, 2023
Primary CompletionJan 12, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.2 years ago

Arms & Interventions

Patients randomized to dose 1 study drugexperimental

Approximately 25 patients randomized to dose 1 of RMP-A03

Drug: RMP-A03 - Dose 1
Patients randomized to dose 2 of study drugexperimental

Approximately 25 patients randomized to dose 2 of RMP-A03

Drug: RMP-A03 - Dose 2
Patients randomized to placeboplacebo_comparator

Approximately 25 patients randomized to placebo.

Drug: RMP-A03 Placebo

Interventions

RMP-A03 - Dose 1drug

Patients will randomized to low dose of RMP-A03

RMP-A03 - Dose 2drug

Patients will be randomized to high dose of RMP-A03

RMP-A03 Placebodrug

Patients will be randomized to RMP-A03 Placebo